Branche, A.; Mulligan, M.J.; Maniar, A.; Puente, O.; Oladipupo, I.; Crowther, G.; Zareba, A.M.; Yi, Z.; Scully, I.; Gomme, E.;
et al. A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines 2025, 13, 383.
https://doi.org/10.3390/vaccines13040383
AMA Style
Branche A, Mulligan MJ, Maniar A, Puente O, Oladipupo I, Crowther G, Zareba AM, Yi Z, Scully I, Gomme E,
et al. A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines. 2025; 13(4):383.
https://doi.org/10.3390/vaccines13040383
Chicago/Turabian Style
Branche, Angela, Mark J. Mulligan, Alok Maniar, Orlando Puente, Islamiat Oladipupo, Graham Crowther, Agnieszka M. Zareba, Zhuobiao Yi, Ingrid Scully, Emily Gomme,
and et al. 2025. "A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults" Vaccines 13, no. 4: 383.
https://doi.org/10.3390/vaccines13040383
APA Style
Branche, A., Mulligan, M. J., Maniar, A., Puente, O., Oladipupo, I., Crowther, G., Zareba, A. M., Yi, Z., Scully, I., Gomme, E., Koury, K., Kitchin, N., Allen, P. S., Anderson, A. S., Gurtman, A., & Lindert, K.
(2025). A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines, 13(4), 383.
https://doi.org/10.3390/vaccines13040383
